OpenAI Acquires Orchestra Bio to Expand Rosalind’s Life Sciences Tools

TL;DR

• OpenAI announced its acquisition of biotech software startup Orchestra Bio on Tuesday.
• Financial terms were not disclosed; Orchestra had reportedly raised around $20 million by 2025.
• The startup builds AI agents for biotech operations, including financial tracking and clinical trial scheduling.
• Orchestra’s team and technology will support Rosalind and Rosalind Workbench.

OpenAI Adds Biotech Software Startup Orchestra Bio

OpenAI has acquired Orchestra Bio, a four-year-old startup developing AI software for biotechnology companies, according to an announcement published Tuesday.

The companies did not disclose the transaction’s financial terms.

Orchestra had reportedly raised approximately $20 million by 2025 from investors including Andreessen Horowitz, Atria and 8VC. That funding figure is separate from the undisclosed acquisition price.

The deal brings Orchestra’s team and technology into OpenAI’s expanding life sciences business.

Orchestra Builds Agents for Biotech Operations

Orchestra develops AI agents designed to help biotechnology companies manage the operational work surrounding drug discovery and development.

Its tools handle tasks ranging from tracking finances to resolving scheduling issues involving clinical trials.

These functions address the coordination and administrative demands of research organizations, rather than focusing solely on scientific analysis.

Adding that operational expertise could help OpenAI connect its research tools with the practical workflows companies use to organize and execute projects.

Team Will Support Rosalind and Its Workbench

OpenAI said Orchestra’s team and technology will contribute to Rosalind, its AI model for life sciences research, and the related Rosalind Workbench.

The Workbench is designed to help researchers plan experiments and analyze results, providing a software environment around the underlying model.

Orchestra’s experience building agents for biotech businesses could broaden those capabilities by supporting coordination across research and operational tasks. OpenAI did not specify which Orchestra features would be integrated first or provide a development timeline.

The company names Moderna and Novo Nordisk among Rosalind’s customers, indicating existing adoption by major pharmaceutical businesses.

Acquisition Reflects AI Labs’ Industry Expansion

The transaction illustrates how major AI developers are expanding beyond general-purpose models into software tailored to specific industries.

In life sciences, that means combining research capabilities with tools that fit pharmaceutical and biotechnology workflows.